About ADMA

ADMA is a late-stage biopharmaceutical company that develops, manufactures and intends to commercialize specialty plasma-based biologics for the treatment and prevention of Primary Immune Deficiency Disease (PIDD) and certain infectious diseases. ADMA's mission is to develop and commercialize plasma-derived, human immune globulins targeted to niche patient populations for the treatment and prevention of certain infectious diseases. The target patient populations include immune-compromised individuals who suffer from an underlying immune deficiency disease, or who may be immune-compromised for medical reasons. ADMA's lead product candidate, RI-002, has completed a Phase III clinical trial in patients with PIDD and has met the primary endpoint. A BLA for RI-002 was submitted to the FDA on July 31, 2015. The company has received U.S. Patent 9,107,906.
Primary Exchange: NASDAQ
SIC Pharmaceutical Preparations
NAICS Pharmaceutical Preparation Manufacturing

ADMA is a Holding In These ETFs:

ETF Ticker ETF Name Net Assets Net Assets Raw # Holdings # Holdings Raw Weight Weight Raw Market Value Market Value Raw
URTY ProShares UltraPro Russell2000 97.7 M 9.76575E+07 2,016 2016 0.0% 8.35135E-06 3 K 2592
UWM ProShares Ultra Russell2000 167.6 M 1.67596E+08 2,016 2016 0.0% 1.23573E-05 4 K 4492
PXSG Invesco Russell 2000 Pure Growth ETF 85.9 M 8.59E+07 301 301 0.21% 0.00214 192 K 191552
VTWG Vanguard Russell 2000 Growth ETF 286.3 M 2.863E+08 1,245 1245 0.01% 7E-05 20 K 20497
VTWO Vanguard Russell 2000 ETF 1.6 B 1.6E+09 2,013 2013 0.0% 4E-05 62 K 61652
ITOT iShares Core S&P Total U.S. Stock Market ETF 18.3 B 1.83396E+10 3,566 3566 0.0% 0 2 K 2264
IWC iShares Microcap ETF 881.6 M 8.81617E+08 1,452 1452 0.02% 0.0002 156 K 155537
IWM iShares Russell 2000 ETF 43.1 B 4.31393E+10 2,005 2005 0.0% 0 1.3 M 1309250
IWO iShares Russell 2000 Growth ETF 8.9 B 8.92227E+09 1,238 1238 0.01% 0.0001 549 K 549083
IWV iShares Russell 3000 ETF 9.5 B 9.51742E+09 2,930 2930 0.0% 0 63 K 63403

Wait, Before You Leave...